Latest Commercialisation News

Memphasys is intensifying its direct sales efforts for the Felix™ sperm-selection device across key Middle East IVF clinics, positioning for rapid market activation upon CE Mark approval expected early 2026.

Sparc Hydrogen has appointed Alana Barlow as its inaugural CEO, marking a strategic move to accelerate commercialisation of its innovative photocatalytic water splitting technology for green hydrogen.

BPM Minerals has kicked off a significant 3,000m drilling campaign at its high-grade Beachcomber Prospect within the Forelands Gold Project, backed by a recent $3.5 million capital raise. Assay results expected early next year will be closely watched for signs of a major new gold resource in Western Australia.

Island Pharmaceuticals has been granted a pivotal US patent extending protection for its antiviral drug Galidesivir as a Covid-19 treatment until 2042, reinforcing its strategic position in the antiviral market.

Sparc Hydrogen has reached a pivotal milestone with sustained hydrogen generation at its Roseworthy pilot plant, advancing its innovative photocatalytic water splitting technology towards commercialisation.

Terragen Holdings has received nearly $1 million in R&D tax incentives, reinforcing its cash position and fueling ongoing development of its innovative agricultural biotech products.

Identitii Limited has announced a pro rata non-renounceable rights issue to raise approximately $2.88 million, partially underwritten by Beauvais Capital Pty Ltd. The funds will support the development and commercialisation of its BNDRY platform amid ongoing patent litigation risks.

Anteris Technologies has secured regulatory green lights for its pivotal PARADIGM trial and raised $25.2 million in capital, advancing its innovative DurAVR® transcatheter heart valve towards commercialisation.

HITIQ Limited has successfully raised $925,000 through an oversubscribed placement, issuing shares at a discount and attaching listed options to support its concussion management technology's commercialisation.

Neurizon Therapeutics has completed manufacturing three GMP registration batches of its lead ALS drug candidate NUZ-001 ahead of schedule, paving the way for FDA submissions and clinical trial enrollment.

4DMedical has expanded its partnership with Philips, securing a US$10 million order commitment to distribute its CT – VQ™ lung imaging technology across North America, aiming to transform pulmonary diagnostics.

Talga Group has applied for a SEK 1.1 billion grant to fund a commercial-scale battery anode plant in Sweden, complementing existing EU funding and securing strong customer interest.